LOS ANGELES, April 25 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Monday expanded its approval of the COVID-19 treatment Veklury, also known as remdesivir, to include pediatric patients 28 days of age and older weighing at least 3 kilograms who are infected by SARS-CoV-2.
This action makes Veklury the first approved COVID-19 treatment for children less than 12 years of age, said the FDA.
